HALB (Halberd) EBIT: $ Mil (TTM As of Jul. 2023)


What is Halberd EBIT?

Halberd HALB EBIT is $ Mil as of Jul. 2023.

Halberd's earnings before interest and taxes (EBIT) for the six months ended in Jul. 2023 was $-0.45 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Halberd's annualized ROC % for the quarter that ended in Jul. 2023 was -12,771.43%. Halberd's annualized ROC (Joel Greenblatt) % for the quarter that ended in Jul. 2023 was -9,933.33%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield.

Halberd  (OTCPK:HALB) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Halberd's annualized ROC % for the quarter that ended in Jul. 2023 is calculated as:

ROC % (Q: Jul. 2023 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Jul. 2022 ) + Invested Capital (Q: Jul. 2023 ))/ count )
=-0.447 * ( 1 - 0% )/( (0.004 + 0.003)/ 2 )
=-0.447/0.0035
=-12,771.43 %

where

Invested Capital(Q: Jul. 2022 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=0.017 - 0.595 - ( 0.01 - max(0, 0.595 - 0.013+0.01))
=0.004

Invested Capital(Q: Jul. 2023 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=0.012 - 0.789 - ( 0.007 - max(0, 0.789 - 0.009+0.007))
=0.003

Note: The Operating Income data used here is one times the annual (Jul. 2023) data.

2. Joel Greenblatt's definition of Return on Capital:

Halberd's annualized ROC (Joel Greenblatt) % for the quarter that ended in Jul. 2023 is calculated as:

ROC (Joel Greenblatt) %(Q: Jul. 2023 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Jul. 2022  Q: Jul. 2023
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=-0.447/( ( (0.005 + max(-0.592, 0)) + (0.004 + max(-0.787, 0)) )/ 2 )
=-0.447/( ( 0.005 + 0.004 )/ 2 )
=-0.447/0.0045
=-9,933.33 %

where Working Capital is:

Working Capital(Q: Jul. 2022 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0 + 0 + 0.003) - (0.595 + 0 + 0)
=-0.592

Working Capital(Q: Jul. 2023 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0 + 0 + 0.002) - (0.789 + 0 + 0)
=-0.787

When net working capital is negative, 0 is used.

Note: The EBIT data used here is one times the annual (Jul. 2023) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Halberd's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Jul. 2023 )
=/0.637
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Halberd EBIT Related Terms

Halberd EBIT Historical Data

* Premium members only.

The historical data trend for Halberd's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Halberd EBIT Chart

Halberd Annual Data
Trend Jul08 Jul22 Jul23
EBIT
-0.04 -1.62 -0.45

Halberd Semi-Annual Data
Jul08 Jul22 Jul23
EBIT -0.04 -1.62 -0.45

HALB vs GRI, OCEA, PCSA: EBIT Comparison

For the Biotechnology subindustry, Halberd's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Halberd EV-to-EBIT vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Halberd's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Halberd's EV-to-EBIT falls into.


Halberd EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

For stock reported annually, GuruFocus uses latest annual data as the TTM data. EBIT for the trailing twelve months (TTM) ended in Jul. 2023 was $ Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBIT →
What does a EBIT of $ Mil mean?
Halberd (HALB) has a EBIT of $ Mil as of Jul. 2023. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Halberd.
Is Halberd's EBIT too high?
Halberd's current EBIT is $ Mil.
How does Halberd's EBIT compare to GRI and OCEA?
Halberd's EBIT of $ Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT for a Biotechnology company?
A good EBIT depends on the Biotechnology industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT mean?
A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Halberd. Halberd's current EBIT is $ Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Halberd stock overvalued right now?
Halberd (HALB) has a current EBIT of $ Mil. The current EBIT is $ Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT calculated?
EBIT is calculated from a company's financial statements. For Halberd (HALB), the current EBIT is $ Mil as of Jul. 2023. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Halberd Business Description

Address P.O. Box 25, Jackson Center, PA, USA, 16133
Halberd Corp is a holding company and acquisition vehicle for established businesses. It is also developing a patented process for disease eradication by removing the pathophysiologic basis of the disease. The company is focused on developing treatments for neurodegenerative diseases, such as PTSD and CTE (Post Traumatic Stress Disorder and Chronic Traumatic Encephalopathy), Alzheimer's Disease, Parkinson's Disease, etc.